Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

The two collaborated on research showing that quantum computing could greatly aid the design of mRNA-based medicines and ...

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

“Coffee filters, unlike paper towels don't contain lint, so they make a great option for cleaning windows, mirrors, and ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Sell rating on Moderna, with a price target of $26.00. The company’s shares closed yesterday at $32.06. Ele ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...